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Purpose 
• To explore the current state of management of postoperative 
nausea and vomiting (PONV) by anesthesia providers 
• To compare the effectiveness of promethazine 6.25 mg to  
promethazine 12.5 mg in the post procedural patient 
experiencing nausea in Phase I and  Phase II
• To compare the known risk factors that precipitate PONV  to 
the factors that influenced PONV in the study population
• To accurately document nausea and reassessment of 
nausea after interventions
Background
• Patients with PONV delay discharge, require more medical 
interventions, increase healthcare costs and decrease 
patient satisfaction
• Larger doses of promethazine increase sedation in post 
operative patients especially in conjunction with opioids
• Promethazine is low cost and has a long elimination half life
• Reassessment of effectiveness of a medication is a JCAHO 
requirement
Assessment
This study took place in the post surgical area of a 500 bed 
magnet facility in the Pacific Northwest. There is variation in 
practice for promethazine dosing. Comparing outcomes of 
differing doses will allow for recommendations for the smallest 
effective dose. Side effects associated with the higher dose 
include:  increased recovery time, increased healthcare costs, 
increased admissions for PONV and decreased patient 
satisfaction.
References
Deitrick, C.L., Mick, D.J., Lauffer, V., Prostka, E., Nowak, D. & Ingersoll, G. (2015). A comparison of two differing doses of promethazine for 
the treatment of postoperative nausea and vomiting. Journal of Peranesthesia Nursing, 30(1), 5‐13. 
http://dx.doi.org//10.1016/j.jopan.2014.01.009.
American Society of PeriAnesthesia Nurses. (2006). PONV / PDNV Clinical Guideline. Retrieved from 
http://www.aspan.org/Clinical-Practice/Clinical-Guidelines/PONV-PDNV
Skledar,S.J, Willams,B.A, Vallejo,M.C., (2007) Eliminating Postoperative Nausea and Vomiting in Outpatient Surger with 
Mulimodal Strategies including Low Doses of Nonsedating, Off-Patent Antiemetics: IS” Zero Tolerance” Achievable?, The 
Scientific World Journal, 7,959-977.
Goals
• To observe for nausea resolution with differing 
doses of promethazine
• To examine the current practice for postoperative 
nausea management 
• Research known risk factors causing PONV and 
compare it to the study population
• Educate staff regarding documentation of nausea 
after interventions and audit for compliance
Intervention
For a period of 2 months, data was collected on the 
number of patients that received promethazine 6.25 mg 
or 12.5 mg intravenously, and whether nausea resolved 
within 30 minutes. 
Out of 2200 patients,  85  met inclusion criteria 
Compliance of nausea reassessment documentation 
was assessed by chart audits in June.  Staff  was 
educated on proper documentation and re-audited in 
July.
.
Evaluation 
• 89% of patients with PONV (n=76) received 6.25 
mg promethazine.  The sample size of 
promethazine 12.5mg was too small to be 
statistically significant
• The 6.25mg IV promethazine dose resolved the 
nausea 86% of the time.
• The sample was comprised of mostly non-
smoking females with an average age of 45 
which reaffirmed known risk factors for PONV
• The length of stay increased in both Phase 1 and 
Phase ll by 15 min and 50 min respectively for 
those receiving promethazine
• Documentation of nausea reassessment 
increased by 14% in the month of July
Next Steps
Partner with anesthesiologists and pharmacists to 
begin a controlled clinical trail comparing 
decreasing doses of promethazine and/or using a 
preemptive dose vs repeating ondansetron.
Review clinical evidence for other nursing 
interventions that may relieve nausea in Phase l 
and Phase ll post operative patients.
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